Galapagos NV
Galapagos NV (ticker: GLPG) is a European biotechnology company focused on discovering and developing small-molecule medicines for diseases with high unmet medical need. With a market capitalisation of about $2.14 billion, Galapagos is R&D-led: its value drivers are clinical trial results, regulatory decisions and partnerships rather than steady product revenues. Investors should note the binary nature of biotech investing — successful trials can materially increase value, while failures or delays can have the opposite effect. The company typically bears high research and development costs and faces clinical, regulatory and commercial risks, as well as competition from larger pharma firms. Before considering an investment, check the latest pipeline updates, cash position and any collaboration terms. This summary is for educational purposes only, not personalised advice. Investment values can fall as well as rise and returns are not guaranteed; consider your own risk tolerance and, if needed, consult a regulated financial adviser.
Stock Performance Snapshot
Financial Health
Galapagos NV is generating strong revenue and cash flow, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GLPG
Oral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: August 13, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical pipeline focus
Galapagos’s value is closely tied to trial readouts and regulatory milestones; positive results can move the stock, though outcomes are uncertain.
Partnership dynamics
Collaborations can fund development and widen commercial reach, but terms and partner performance influence long‑term returns.
Industry context
Operates in a competitive global biotech market where innovation drives opportunity, yet clinical and regulatory risks mean performance can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
